Azitra (NYSEAMERICAN:AZTR – Get Free Report) issued its earnings results on Wednesday. The company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.05), FiscalAI reports.
Azitra Price Performance
Shares of NYSEAMERICAN AZTR remained flat at $0.14 during mid-day trading on Thursday. The company had a trading volume of 458,548 shares, compared to its average volume of 9,958,968. Azitra has a 12 month low of $0.10 and a 12 month high of $1.40. The firm’s fifty day simple moving average is $0.16 and its 200 day simple moving average is $0.20.
About Azitra
Azitra Inc is a clinical-stage biopharmaceutical company focused on developing live bacterial therapies for dermatological conditions. Headquartered in Cambridge, Massachusetts, the company leverages its proprietary ActoBiotic platform to formulate topical treatments that aim to modulate the skin’s native microbial ecosystem.
The company’s lead investigational therapies are being evaluated in early-phase clinical studies for inflammatory skin disorders, including atopic dermatitis and other conditions characterized by microbial imbalance.
Read More
- Five stocks we like better than Azitra
- Riot Platforms Re-Wires the Ledger for a $9B AI Power Play
- Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?
- Joby’s Defense Pivot Accelerates With $500M Resonant Sciences Deal
- Lumentum Just Delivered the AI Growth Investors Wanted
Receive News & Ratings for Azitra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Azitra and related companies with MarketBeat.com's FREE daily email newsletter.
